Bon Secours Cork Cancer Centre
@BonsCancerCork
Followers
414
Following
187
Media
33
Statuses
195
Providing high-quality cancer care locally in Cork. Surgical, medical and radiation oncology care within the same building. Focused on cancer clinical trials
Bon Secours Hospital Cork
Joined December 2021
🔔 #TAORMINA clincial trial opened @BonSecours & @UPMCinIreland under the leadership of site PI @ThisIsKathyRock & co-PI @Deirdreomahon14 Helping expand access to innovative cancer treatment 🔬 🇮🇪 https://t.co/lOLSxtZU4Q
@cancertrials_ie @IRROGTrials #SABR #BreastCancerTrials
0
3
8
Celebrating #InternationalClinicalTrialsDay 🌍 with our incredible team and colleagues here at Bon Secours Cork Cancer Centre. “Teamwork divides the task and multiplies the success”. @cancertrials_ie
0
6
24
2️⃣ 2nd patient randomised on the MK2870-012 trial! 🎉 Grateful for our dedicated team and courageous patients in contributing to advancing new treatment options ✨@conlethmurphy 💡trial details:
merckclinicaltrials.com
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice...
1
4
10
0
0
0
1️⃣ First patient randomized in the MK2870-010 trial offering Sacituzumab Tirumotecan alone or in combination with Pembrolizumab vs. Standard treatment for unresectable locally advanced/MBC! 🎉 👏 Huge thanks to our team & brave patients for reaching this milestone
4
6
29
Excited to share the news that our cancer centre has been officially certified by ASCO 🎉 Patient-centred care is our focus, and we’re proud to meet expert-backed oncology medical home standards. A great start to #WorldCancerDay 🌎🎗️. Thank you @ASCO @IrishCancerSoc
1
10
60
2025 off to a great start with the 1st patient in 🇮🇪 randomised to the MK2870-012 trial offering Sacituzumab Tirumotecan (MK2870) plus Pembrolizumab vs TPC to patients with TNBC who did not achieve pCR, led by PI @conlethmurphy Trial details:
1
1
3
The MK2870-010 trial now open to recruitment @BSHSIreland offering Sacituzumab Tirumotecan as single agent and in combination with Pembrolizumab vs TPC to patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer 💡Trial details
1
0
4
0
0
1
The MK2870-012 trial initiated @BonsCancerCork this week offering Sacituzumab Tirumotecan (MK2870) plus Pembrolizumab vs treatment of physicians choice to patients with TNBC who did not achieve pCR 💡Trial details: https://t.co/Ed3GmR5JfI
@UCCCancerTrials @cancertrials_ie
1
4
14
Delighted to announce the VASA Pro trial based in @BonsCancerCork had recruited its first patients this week. This trial investigates if acupuncture can reduce symptoms in men undergoing hormone therapy for prostate cancer. #ProstateCancer #MensHealth
0
6
10
🌟3rd patient randomised on the Ember-4 trial 3️⃣👏 @Deirdreomahon14 💡trial details https://t.co/fQT5Wat1iu
@UCCCancerTrials @CanResUCC @hrbireland @BreakthroCancer @CRF_CORK @cancertrials_ie @IrishCancerSoc
trials.lilly.com
1
1
12
🌟 2 patients randomised on the Ember-4 trial this week👏 PI @Deirdreomahon14 💡Trial details: https://t.co/fQT5Watz82
@UCCCancerTrials @CRF_CORK @cancertrials_ie @CanResUCC @hrbireland @BreakthroCancer @IrishCancerSoc
trials.lilly.com
0
4
17
Happy #ICTD2024, thank you to all the brave patients who participate in trials 🌟 and all the nurses, doctors, pharmacists, clerical, and many more who support the running of #clinicaltrials @UCCCancerTrials @CanResUCC
0
5
39
📢🗓️**MEMBERS**🗓️📢 The Spring DSSG meetings will take place on Friday 22nd March 2024. The meetings will be held in RCSI, Dublin 2. Members may attend virtually or in-person. Meeting times, an agenda for the day, and other details will be published in the coming weeks.
0
6
15
🌟 This week we recruited the 1st patient in the Republic of Ireland 🇮🇪 into the #clinicalTrial PACE-NODES. #teamwork @UPMCHillmanCC @BonsCancerCork PACE-NODES investigates giving a short high dose course of pelvic lymph node #Radiotherapy for high risk localised #ProstateCancer
2
6
24